No Prescription |
 |
 | ||
|
Sterineb Respules Atrovent Respules |
|
| ||
No Prescription » Prescription Drugs 15 » Sterineb Respules Atrovent Respules Ipratropium is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema and when used concomitantly with inhaled beta-agonists for asthma.Respules: Adults (including elderly) and adolescents over 12 years of age:Maintenance Treatment: 1 respule 3 to 4 times daily Acute Attacks: 1 respule; repeated doses can be administered until the patient is stable. The time interval between doses may be determined by the physician. Paediatric Respules:Children 6 to 12 years: 1 respule; repeated doses can be administered until the patient is stable. The time interval may be determined by the physician. Daily dosage exceeding 1mg in children under 12 years of age should be given under medical supervision. Under 6 years of age: 1 respule; should be given under medical supervision repeated doses can be administered until the patient is stable. The time interval may be determined by the physician. Ipratropium respules are commonly used in combination with 2-agonist to maximise bronchodilation.IPRATROPIUM RESPULES can be administered using a range of commercially available nebulising devices. Where wall oxygen is available it is best administered at a flow rate of 6 - 8 litres per minute.IPRATROPIUM Respules and disodium cromoglycate inhalation solutions that contain the preservative benzalkonium chloride should not be administered simultaneously in the same nebuliser as precipitation may occur. Buy Sterineb Respules Atrovent Respules and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About Sterineb Respules Atrovent Respules: Product Type: Prescription Drugs 15 Sterineb Respules ( Atrovent Respules Generic Ipratropium bromide ) Sterineb Respules (Atrovent Respules Generic Ipratropium bromide) Atrovent Respules Generic Ipratropium bromide 250mcg/mL 20 Respules 250mcg/mL 60 Respules 250mcg/mL 40 Respules 500mcg/1mL 60 Respules 500mcg/mL 20 Respules 500mcg/mL 40 Respules Atrovent Respules Generic Ipratropium bromide Sterineb Respules
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
